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Background: β-lactam allergy is the most commonly reported medication allergy and it remains a key issue in
antibiotic prescribing. A detailed and accurate history taking play a key role in preventing potentially serious clinical
incidents and it may contribute in reducing costs.
Methods: Data were collected for patients with a documented penicillin allergy on their drug chart during a six
month period. Sources included the inpatient drug charts and medical notes. Adherence to hospital guidelines was
audited and costs of treatments were calculated.
Results: 94 patients with a history of penicillin allergy were included. Compliance with the hospital antibiotic policy
was 81% and 52% of cases had a description of the reaction documented. The mean additional cost per patient
was £89.29 (excluding VAT).
Conclusions: It is important to maintain a high level of vigilance and constantly educate all healthcare professionals
involved in prescribing and dispensing antibiotics in order to avoid the unnecessary use of non-penicillin-based
antibiotics and associated cost implication.
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β-lactam allergy is the most commonly reported medica-
tion allergy and it is self-reported by at least 10% of
patients. However, 90% of these individuals are found not
to be allergic and are able to tolerate penicillins [1]. In
many cases, β-lactam exposure might not actually have
occurred, or patients may have had non-immunologic
adverse events such as vomiting, diarrhea, or nonspecific
rash, other non-toxic effects or contemporaneous side
effects inappropriately attributed to the drug. These pa-
tients actually tolerate all β-lactams [2]. Inappropriate
labeling of a patient as “penicillin allergic” can have a
major impact on patient safety, the use of restricted antibi-
otics and the hospital budget.
As advised by BSACI (British Society of Allergy and
Clinical Immunology) guidelines on drug allergy [3] every
patient should be questioned about his/her allergy status
prior to any drug prescription and results should be
clearly recorded in the medical notes and drug chart. In
addition, national and local antibiotic policies frequently* Correspondence: giovanni.satta@nhs.net
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reproduction in any medium, provided the orgive an alternative antibiotic choice in case penicillin can-
not be used.
However, despite the presence of national and local
guidance, compliance remains low. A recent Canadian
study of inpatients on intensive care, coronary care or
medicine wards found that the nature of the penicillin
allergy was described in only 30% of cases [4]. This value
matches with compliances of 33% in an outpatients set-
ting of family medicine clinics [5] and 34% in inpatient
charts [6].
As the options for the treatment of infections become
more limited and increasingly costly due to the emer-
gence of highly resistant organisms, it is important that
we make the best use of the antibiotics available. In the
hospital setting we are familiar with the use of evidence
based guidelines to aid the appropriate prescribing of
antibiotics, but quite often we fail to investigate the na-
ture of antibiotic allergies which may preclude the use of
cheap, effective agents. Antibiotics that are used more
frequently and over a longer period of time have a
higher prevalence of allergy. Additional risk factors
include increasing age and female sex [7,8].
Based on this current lack of adherence and the need
of a greater antibiotics stewardship, we decided to carry
out an audit on the compliance with national and locald. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tackle the main areas requiring improvements.
Methods
We performed an audit to challenge history taking,
documentation and compliance with hospital guidelines
as regards β-lactam allergy. Data were collected on pa-
tients with a reported β-lactam allergy and treated with
antibiotics in a tertiary university hospital (Royal Free
London) during a 6 months period.
We evaluated compliance with the following stan-
dards: allergy history taken, documentation in the drug
chart, more detailed documentation clarifying the nature
of the allergy written in the medical notes and prescrip-
tion made according to current antibiotic guidelines.
Impact on clinical management and costs were also eval-
uated. Data were collected by a microbiologist/pharma-
cist using a predefined audit proforma.
Results and discussion
We collected information on 94 patients who gave a his-
tory of penicillin allergy over a period of 6 months. The
median age was 65 years (19–95) with a 1:2 male/female
ratio. All medical and surgical specialties were repre-
sented. Chest infection was the commonest reason for
the use of antibiotics (26%), followed by skin and soft
tissue (18%), urinary tract and abdominal infections
(both 16%) and sepsis of unknown origin (5%).
There was 100% compliance in recording penicillin al-
lergy in the drug chart and in the medical notes and
81% of prescriptions were compliant with hospital anti-
biotic policy and/or were approved by Microbiology.
However, in 19% of cases, no allergy history was re-
corded in the electronic notes (Cerner) and in only 52%
of cases was the penicillin allergy better specified
explaining the type of reaction. In this last group, rash
was the commonest drug reaction noted (52%), followed
by anaphylaxis (17%), other allergic symptoms (10%),
gastrointestinal symptoms (10%) and unknown (5%).
The term “intolerance” was written in an additional 6%
of the notes but the clinical significance of this term was
not explained and it was therefore unhelpful in under-
standing the type of reaction. Interestingly, only one pa-
tient out of 94 was referred for an allergology review
and had a skin test performed.
With regard to patient safety, in three cases a
penicillin-based antibiotic was wrongly prescribed and
these constituted serious clinical incidents. In another
two cases, the clinical teams discussed the nature of
penicillin allergy with patient, family or GP and decided
to use a penicillin-based antibiotic as the reaction was
considered to be non-significant. In all cases, no allergic
reactions were recorded. The history of β-lactam allergy
did not have any impact on the choice of antibiotics in30% of cases – the patients were commenced on non-
penicillin-based antibiotics for other reasons, predomin-
antly multi-resistant pathogens.
As regards costs, the total acquisition cost (excluding
VAT) of antibiotics for the penicillin allergic group was
£17,849 compared with £9,831 for equivalent treatment
in non-allergy (based on hospital guidelines). This con-
stitutes a mean extra cost per patient of £89.29. The
commonest non-penicillin based alternative that was
prescribed was a fluoroquinolone (30%), followed by a
carbapenem (17%), a macrolide (14%), a glycopeptide
(10%), an aminoglycoside (9%) and various combinations
of these or other antibiotics.
Overall, the documentation of β-lactam allergy and
compliance with guidelines were good, although the data
were likely biased by the selection process. As regards
clarification of the nature of the allergy, there is still
scope for considerable improvement, even if our result
(52%) is much higher than the reports previously de-
scribed in the literature. Female sex and older age were
confirmed as risk factors. Also β-lactam allergy still re-
mains a key issue in antibiotic prescribing with potential
clinical incidents. It is important to distinguish non-
allergic reaction from true allergy (and the type of
reaction), as this will have an important impact on the
antibiotic choice. Although a myth persists that approxi-
mately 10% of patients with a history of penicillin allergy
will have an allergic reaction if given a cephalosporin, a re-
cent review showed that the overall cross-reactivity rate is
approximately 1% (in particular when using first and sec-
ond generations) [9]. In addition, it appears to be little/no
potential cross reactivity between meropenem and penicil-
lins even in patients with a definite history of anaphylactic
reactions to penicillins [10].
There are clear cost-implications associated with β-
lactam allergy. One previous paper has evaluated this in
a community setting with calculated extra costs of $10.53
(~ £7) per patient [5] and three in the hospital setting with
average additional costs of Can$91.12 (~£54) [4], €159
(~ £136) [11] and US$212.10 (~£132) [12]. The signifi-
cantly higher hospital costs were attributed to increased
expenditure on intravenous antibiotics instead of oral for-
mulations. A history of penicillin allergy has also been as-
sociated with an increased length of stay and total cost of
admission [13]. These cost-implications might be hidden
by the rising prevalence of bacterial resistance and conse-
quent use of non-penicillin-based alternatives. It should
also be considered that a comparison of acquisition costs
alone is unlikely to accurately reflect the total costs in-
curred when using treatments with significant toxicities
or reduced efficacy [14].
Considering all these implications, we could suggest
that all patients with a query penicillin allergy should be
referred to a specialist for skin test and/or further tests.
Satta et al. Clinical and Molecular Allergy 2013, 11:2 Page 3 of 3
http://www.clinicalmolecularallergy.com/content/11/1/2The main limitations against this would be the inability
of services to cope with the increased demand, the pos-
sible non cost-effectiveness or simply general practi-
tioners and hospital teams too busy (and not used to) to
organize an additional referral for a non urgent problem.
The main indications for skin testing should be the lack
of an alternative antibiotic option and patients with re-
current infections and multiple allergies (thus with a
limited choice of antibiotics). Education and training re-
main key issues.
Conclusions
β-lactam allergy still remains a key issue in antibiotic
prescribing. In order to protect patients, rationalize anti-
biotic prescribing and reduce costs, it is important to
maintain a high level of vigilance and constantly educate
all healthcare professionals. The need for detailed and
accurate history taking, documentation, eventual referral
to an allergy specialist, as well as an increased awareness
and knowledge of possible alternative antibiotics, are the
main areas where education and training are still
required.
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